Neuropeptides
Volume 43, Issue 6 , Pages 457-463 , December 2009

NPY regulation of bone remodelling

  • Nicola J. Lee

      Affiliations

    • Neuroscience Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia
    • ,
  • Herbert Herzog

      Affiliations

    • Neuroscience Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia
    • Faculty of Medicine, University of NSW, Sydney, NSW, Australia
    • Corresponding Author InformationCorresponding author. Address: Neuroscience Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia. Tel.: +61 2 9295 8296; fax: +61 2 9295 8281.

References 

  1. Ahmed M, Bjurholm A, Kreicbergs A, Schultzberg M. Neuropeptide Y, tyrosine hydroxylase and vasoactive intestinal polypeptide-immunoreactive nerve fibers in the vertebral bodies, discs, dura mater, and spinal ligaments of the rat lumbar spine. Spine. 1993;18(2):268–273
  2. Ahn JD, Dubern B, Lubrano-Berthelier C, Clement K, Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology. 2006;147(7):3196–3202
  3. Allison, S., Baldock, P., Enriquez, R., Lin, E., During, M., Gardiner, E., Eisman, J., Sainsbury, A., Herzog, H., 2008. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J. Bone Miner. Res.
  4. Allison SJ, Baldock P, Sainsbury A, Enriquez R, Lee NJ, Lin EJ, et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. The Journal of Biological Chemistry. 2006;281(33):23436–23444
  5. Amano S, Arai M, Goto S, Togari A. Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim. Biophys. Acta. 2007;1770(6):966–973
  6. Baldock PA, Allison S, McDonald MM, Sainsbury A, Enriquez RF, Little DG, et al. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J. Bone Miner. Res. 2006;21(10):1600–1607
  7. Baldock PA, Allison SJ, Lundberg P, Lee NJ, Slack K, Lin EJ, et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. The Journal of Biological Chemistry. 2007;282(26):19092–19102
  8. Baldock PA, Sainsbury A, Allison S, Lin EJ, Couzens M, Boey D, et al. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J. Bone Miner. Res. 2005;20(10):1851–1857
  9. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 2002;109(7):915–921
  10. Baron, R., 1999. Anatomy and ultrastructure of bone. In: Favus, M.F. (Ed.), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, fourth ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp. 3–10.
  11. Bjurholm A. Neuroendocrine peptides in bone. Int. Orthop. 1991;15(4):325–329
  12. Bjurholm A, Kreicbergs A, Schultzberg M, Lerner UH. Parathyroid hormone and noradrenaline-induced enhancement of cyclic AMP in a cloned osteogenic sarcoma cell line (UMR 106) is inhibited by neuropeptide Y. Acta Physiol. Scand. 1988;134(3):451–452
  13. Bjurholm, A., Kreicbergs, A., Schultzberg, M., Lerner, U.H., 1992. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 7(9), 1011–1019.
  14. Bjurholm A, Kreicbergs A, Terenius L, Goldstein M, Schultzberg M. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J. Auton. Nerv. Syst. 1988;25(2–3):119–125
  15. Blomqvist AG, Herzog H. Y-receptor subtypes – how many more?. Trends Neurosci. 1997;20(7):294–298
  16. Cerda-Reverter JM, Larhammar D. Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution. Biochem. Cell Biol. 2000;78(3):371–392
  17. Cho YR, Kim CW. Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochemical and Biophysical Research Communications. 2004;314(3):773–780
  18. Cornish, J., Callon, K.E., King, A.R., Cooper, G.J., Reid, I.R., 1998. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am. J. Physiol. 275(4 Pt 1), E694–E699.
  19. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197–207
  20. Duong LT, Rodan GA. Regulation of osteoclast formation and function. Rev. Endocrinol. Metab. Disord. 2001;2(1):95–104
  21. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept. 1984;8(3):225–235
  22. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514–520
  23. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. USA. 2008;105(13):5266–5270
  24. Gehlert DR. Introduction to the reviews on neuropeptide Y. Neuropeptides. 2004;38(4):135–140
  25. Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL. Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. The Journal of Biological Chemistry. 1995;270(45):26758–26761
  26. Gordeladze JO, Reseland JE. A unified model for the action of leptin on bone turnover. J. Cell Biochem. 2003;88(4):706–712
  27. Gregor P, Feng Y, DeCarr LB, Cornfield LJ, McCaleb ML. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. The Journal of Biological Chemistry. 1996;271(44):27776–27781
  28. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423(6937):349–355
  29. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J. Bone Miner. Res. 2003;18(12):2180–2189
  30. Herzog H, Darby K, Ball H, Hort Y, Beck-Sickinger A, Shine J. Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation. Genomics. 1997;41(3):315–319
  31. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. USA. 1992;89(13):5794–5798
  32. Hill EL, Elde R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 1991;264(3):469–480
  33. Idris AI, van‘t Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 2005;11(7):774–779
  34. Ishizuka K, Hirukawa K, Nakamura H, Togari A. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci. Lett. 2005;379(1):47–51
  35. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 2006;17(12):1726–1733
  36. Keffel S, Schmidt M, Bischoff A, Michel MC. Neuropeptide-Y stimulation of extracellular signal-regulated kinases in human erythroleukemia cells. J. Pharmacol. Exp. Ther. 1999;291(3):1172–1178
  37. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89(5):755–764
  38. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 1998;393(6680):72–76
  39. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat. Med. 2007;13(7):803–811
  40. Larhammar D, Blomqvist AG, Soderberg C. Evolution of neuropeptide Y and its related peptides. Comp. Biochem. Physiol. C. 1993;106(3):743–752
  41. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–469
  42. Lundberg JM, Martinsson A, Hemsen A, Theodorsson-Norheim E, Svedenhag J, Ekblom B, et al. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochemical and Biophysical Research Communications. 1985;133(1):30–36
  43. Lundberg JM, Terenius L, Hokfelt T, Martling CR, Tatemoto K, Mutt V, et al. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol. Scand. 1982;116(4):477–480
  44. Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. The Journal of Biological Chemistry. 2007;282(26):19082–19091
  45. Lundberg P, Lerner UH. Expression and regulatory role of receptors for vasoactive intestinal peptide in bone cells. Microsc. Res. Tech. 2002;58(2):98–103
  46. Mackie, K., 2008. Signaling via CNS cannabinoid receptors. Mol. Cell Endocrinol. 286(Suppl. 1–2), S60–S65.
  47. Mannon, P.J., Mele, J.M., 2000. Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. Biochem. J. 350(Pt 3), 655–661.
  48. Marks SC, Odgren PR. Structure and development of the skeleton. In:  Bilezikian JP,  Raisz LG,  Rodan GA editor. Principles of Bone Biology. second ed.. San Diedo, CA: Academic Press; 2002;p. 3–15
  49. Matsumoto M, Nomura T, Momose K, Ikeda Y, Kondou Y, Akiho H, et al. Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. The Journal of Biological Chemistry. 1996;271(44):27217–27220
  50. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004;350(5):459–468
  51. Misra M, Miller KK, Tsai P, Gallagher K, Lin A, Lee N, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 2006;91(3):1027–1033
  52. Mori T, Ogata T, Okumura H, Shibata T, Nakamura Y, Kataoka K. Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochemical and Biophysical Research Communications. 1999;262(2):418–422
  53. Motulsky, H.J., Michel, M.C., 1988. Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am. J. Physiol. 255(6 Pt 1), E880–E885.
  54. Mundy, G.R., 1999. Bone remodeling. In: Favus, M.F. (Ed.), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, fourth ed. Lippincott Williams and Wilkins, Philadelphia, PA. pp. 30–38.
  55. Nakamura M, Sakanaka C, Aoki Y, Ogasawara H, Tsuji T, Kodama H, et al. Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors. The Journal of biological chemistry. 1995;270(50):30102–30110
  56. Nie M, Selbie LA. Neuropeptide Y Y1 and Y2 receptor-mediated stimulation of mitogen-activated protein kinase activity. Regul. Pept. 1998;75–76:207–213
  57. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89(5):765–771
  58. Rodan GA. The development and function of the skeleton and bone metastases. Cancer. 2003;97(Suppl. 3):726–732
  59. Sainsbury A, Baldock PA, Schwarzer C, Ueno N, Enriquez RF, Couzens M, et al. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol. Cell Biol. 2003;23(15):5225–5233
  60. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010–2018
  61. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, et al. Central control of bone remodeling by neuromedin U. Nat. Med. 2007;13(10):1234–1240
  62. Shih C, Bernard GW. Calcitonin gene related peptide enhances bone colony development in vitro. Clin. Orthop. Relat. Res. 1997;334:335–344
  63. Sisask G, Bjurholm A, Ahmed M, Kreicbergs A. The development of autonomic innervation in bone and joints of the rat. J. Auton. Nerv. Syst. 1996;59(1–2):27–33
  64. Tabarowski Z, Gibson-Berry K, Felten SY. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochem. 1996;98(4):453–457
  65. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–317
  66. Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol. Pharmacol. 2006;70(3):786–792
  67. Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 2008;22(1):285–294
  68. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. USA. 1982;79(18):5485–5489
  69. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y – a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296(5858):659–660
  70. Teixeira, L., Sousa, D.M., Nunes, A.F., Sousa, M.M., Herzog, H., Lamghari, M., 2009. NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J. Cell Biochem.
  71. Utz AL, Lawson EA, Misra M, Mickley D, Gleysteen S, Herzog DB, et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone. 2008;43(1):135–139
  72. van der Velde M, Delhanty P, van der Eerden B, van der Lely AJ, van Leeuwen J. Ghrelin and bone. Vitam. Horm. 2008;77:239–258
  73. van’t Hof RJ, Macphee J, Libouban H, Helfrich MH, Ralston SH. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology. 2004;145(11):5068–5074
  74. Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby MR, et al. Cloning and expression of a novel neuropeptide Y receptor. The Journal of Biological Chemistry. 1996;271(28):16435–16438
  75. Wortley KE, Garcia K, Okamoto H, Thabet K, Anderson KD, Shen V, et al. Peptide YY regulates bone turnover in rodents. Gastroenterology. 2007;133(5):1534–1543
  76. Xiong Z, Cheung DW. ATP-dependent inhibition of Ca2+-activated K+ channels in vascular smooth muscle cells by neuropeptide Y. Pflugers Arch. 1995;431(1):110–116
  77. Yang K, Guan H, Arany E, Hill DJ, Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J. 2008;22(7):2452–2464
  78. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 2007;13(7):791–801

PII: S0143-4179(09)00089-4

doi: 10.1016/j.npep.2009.08.006

Neuropeptides
Volume 43, Issue 6 , Pages 457-463 , December 2009

Article Tools

* Image Usage & Resolution